Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2025-05-30 Director's Dealing
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Steven D. Rubin
Director's Dealing Classification · 98% confidence The document explicitly mentions 'Form 4 Interested party transaction - Rubin' and is filed with the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE). Form 4 in the US context typically relates to insider transactions (Director's Dealing). The text states, 'Attached hereto is a report on *Form 4 Interested party transaction - Rubin*'. Given the short length (1802 chars) and the nature of reporting a transaction by an interested party/insider, this strongly aligns with the definition of Director's Dealing (DIRS). Although it references a Form 4, which is an SEC filing, the context here is an Israeli regulatory filing reporting an interested party transaction, which is functionally equivalent to insider trading disclosure.
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Director's Dealing Classification · 100% confidence The document explicitly states 'FORM 4' at the top and is titled 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934'. Form 4 filings report personal share transactions by company directors and executives (insider trades). This directly corresponds to the definition for Director's Dealing (DIRS). Although the content details stock options and acquisitions, the document type itself is the SEC Form 4.
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Director's Dealing Classification · 98% confidence The document explicitly mentions 'Form 4 Interested party transaction - Nabel' and reports on transactions by an interested party (likely an insider or director) filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. Form 4 in the US context relates to insider transactions. Among the provided definitions, 'Director's Dealing' (DIRS) is the most appropriate category for reporting personal share transactions by company directors and executives (insider trades). Although the filing format references Israeli regulations, the substance aligns perfectly with insider transaction reporting.
2025-05-30 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Director's Dealing Classification · 99% confidence The document explicitly contains the header "FORM 4" and "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". Form 4 is a mandatory SEC filing used by corporate insiders (directors, officers, or 10% owners) to report changes in their beneficial ownership of the company's securities. This specific filing reports the acquisition of stock options (Derivative Securities) by Adam Logal, Sr. Vice President, CFO of OPKO Health, Inc. This directly corresponds to the definition of Director's Dealing (insider trades). While the document is an SEC filing, the most specific category provided that covers insider transactions is 'Director's Dealing' (DIRS). It is not a general regulatory filing (RNS) because it is a highly specific form type (Form 4). It is not a 10-K, ER, or IR, as it deals with insider transactions, not comprehensive financial performance.
2025-05-30 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Report Publication Announcement Classification · 95% confidence The document explicitly mentions 'Form 4 Interested party transaction - Logal' and references the 'Israel Securities Authority' and 'Tel Aviv Stock Exchange'. Form 4 in the US context relates to insider transactions (Director's Dealing). Although the document is filed via the Israeli system (MAGNA), the content describes a transaction by an interested party/insider, which aligns closely with the definition of Director's Dealing (DIRS). However, the document is an 'Immediate Report' stating 'Attached hereto is a report on *Form 4 Interested party transaction - Logal*'. Given the short length (1802 chars) and the nature of announcing an attached report, this fits the 'Report Publication Announcement' (RPA) category better than classifying it as the underlying transaction report itself, as per Rule 2 ('MENU VS MEAL'). Since 'Director's Dealing' (DIRS) is a specific type of filing, and this document is announcing the filing/attachment of that specific report, RPA is the most accurate classification for this announcement wrapper.
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Jane H. Hsiao, Ph.D.
Director's Dealing Classification · 99% confidence The document contains the standard header information for a US SEC filing, including OMB approval numbers, Issuer Name (OPKO Health, Inc.), and specific form sections like 'Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned' and 'Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned'. The filing is explicitly identified as a 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES' filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. This type of filing, which reports insider transactions (director/officer trades), corresponds to Form 4, which is not explicitly listed in the provided codes. However, the definition for 'Director's Dealing' (Code: DIRS) is 'Report of personal share transactions by company directors and executives (insider trades)'. This is the most accurate classification among the available options for a Form 4 filing.
2025-05-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.